Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials

@article{Noble2011PirfenidoneIP,
  title={Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials},
  author={Paul W. Noble and Carlo Albera and Williamson Z. Bradford and Ulrich Costabel and Marilyn K. Glassberg and David Kardatzke and Talmadge E King and Lisa H Lancaster and Steven A. Sahn and Javier B Szwarcberg and Dominique Valeyre and Roland M. du Bois},
  journal={The Lancet},
  year={2011},
  volume={377},
  pages={1760-1769}
}

Figures and Tables from this paper

A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.

Pirfenidone, as compared with placebo, reduced disease progression, as reflected by lung function, exercise tolerance, and progression-free survival, in patients with idiopathic pulmonary fibrosis.

Pirfenidone should be prescribed for patients with idiopathic pulmonary fibrosis

Patients treated with pirfenidone had slower rates of decline in lung volume and vital capacity than placebo, and in three studies, the results were statistically significant.

Pirfenidone: in idiopathic pulmonary fibrosis.

Patients with IPF who received pirfenidone had an acceptable tolerability profile in clinical trials, with most adverse events being mild to moderate in severity.

Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial

Long-term exposure to macitentan was well tolerated with a similar, low incidence of elevated hepatic aminotransferases in each treatment group, and the primary objective was not met.

Pirfenidone for idiopathic pulmonary fibrosis, thrombocytosis in chronic obstructive pulmonary disease exacerbations, and a longitudinal study on e-cigarettes.

This study confirmed the promise and efficacy of pirfenidone noted in the prior two CAPACITY trials, and FVC and 6-minute-walk distances were maintained for longer periods of time in patients on pirfenidsone.

The role of pirfenidone in the treatment of idiopathic pulmonary fibrosis

The efficacy data, coupled with long-term safety data, provide further evidence of a clinically-meaningful treatment effect with pirfenidone in patients with IPF.

Pirfenidone in idiopathic pulmonary fibrosis: the CAPACITY program

Positive results were obtained in two almost identical double-blind placebo-controlled studies assessing the effects of pirfenidone on change in forced vital capacity, the primary end point, over a 72-week period.

Double-Blind Randomized Trial of Pirfenidone in Chinese Idiopathic Pulmonary Fibrosis Patients

It is shown that pirfenidone combined with high-dose NAC prolonged the progression-free survival of Chinese IPF patients with mild to moderate impairment of pulmonary function and n-acetylcysteine exerted antioxidant and antifibrotic effects on IPF cases.

Pirfenidone: A Review of Its Use in Idiopathic Pulmonary Fibrosis

Oral pirfenidone is a valuable agent for use in patients with IPF and a prespecified mortality analysis across all three studies demonstrated a significant reduction in IPF-related and all-cause mortality with pirfenidsone.
...

References

SHOWING 1-10 OF 38 REFERENCES

Pirfenidone in idiopathic pulmonary fibrosis

Although photosensitivity, a well-established side-effect of pirfenidone, was the major adverse event in this study, it was mild in severity in most of the patients and relatively well tolerated in patients with IPF.

Pirfenidone in idiopathic pulmonary fibrosis: A phase III clinical trial in Japan

Although photosensitivity, a well established side effect of pirfenidone, was the major adverse event in this study, it was mild in severity in most of the patients and relatively well tolerated in patients with IPF.

Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis.

Treatment with pirfenidone improved VC and prevented acute exacerbation of IPF during the 9 months of follow-up, and adherence to treatment regimen was similar between pirfenidsone and placebo groups.

A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.

In a well-defined population of patients with idiopathic pulmonary fibrosis, interferon gamma-1b did not affect progression-free survival, pulmonary function, or the quality of life.

High-dose acetylcysteine in idiopathic pulmonary fibrosis.

Therapy with acetylcysteine at a dose of 600 mg three times daily, added to prednisone and azathioprine, preserves vital capacity and DL(CO) in patients with idiopathic pulmonary fibrosis better than does standard therapy alone.

Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results.

In a randomized, placebo-controlled trial of patients with mild to moderate IPF followed for 96 weeks, imatinib did not affect survival or lung function.

BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.

The primary objective in the Bosentan Use in Interstitial Lung Disease-3 trial was not met and bosentan was well tolerated.

Non-steroid agents for idiopathic pulmonary fibrosis (Intervention Review)

To assess the efficacy of non-steroid agents in adults with idiopathic pulmonary fibrosis, 15 trials involving 10 different drugs were included and survival outcomes were combined using Peto odds ratios or hazard ratios.

Non-steroid agents for idiopathic pulmonary fibrosis.

Pirfenidone appears to improve progression-free survival and, to a lesser extent, pulmonary function in patients with idiopathic pulmonary fibrosis, and more data are needed on overall survival and quality of life on treatment.